About Tandem Diabetes Care, Inc.
https://www.tandemdiabetes.comTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
CEO
John F. Sheridan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-10-10 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 159
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Stifel
Buy
Baird
Outperform
Oppenheimer
Outperform
RBC Capital
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:12.1M
Value:$252.56M
BLACKROCK INC.
Shares:11.12M
Value:$232.13M
VANGUARD GROUP INC
Shares:7.06M
Value:$147.41M
Summary
Showing Top 3 of 319
About Tandem Diabetes Care, Inc.
https://www.tandemdiabetes.comTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $249.25M ▲ | $154.35M ▼ | $-21.16M ▲ | -8.49% ▲ | $-0.31 ▲ | $-18.59M ▲ |
| Q2-2025 | $240.68M ▲ | $177.66M ▼ | $-52.4M ▲ | -21.77% ▲ | $-0.78 ▲ | $-50.82M ▲ |
| Q1-2025 | $234.42M ▼ | $239.28M ▲ | $-130.56M ▼ | -55.69% ▼ | $-1.97 ▼ | $-116.42M ▼ |
| Q4-2024 | $282.65M ▼ | $158.04M ▲ | $755K ▲ | 0.27% ▲ | $0.01 ▲ | $6.12M ▲ |
| Q3-2024 | $363.29M | $150.75M | $-23.25M | -6.4% | $-0.35 | $-16.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $319.11M ▲ | $874.65M ▼ | $741.69M ▼ | $132.97M ▼ |
| Q2-2025 | $315.36M ▼ | $875.74M ▼ | $742.45M ▼ | $133.28M ▼ |
| Q1-2025 | $368.63M ▼ | $922.14M ▼ | $766.85M ▲ | $155.29M ▼ |
| Q4-2024 | $438.33M ▼ | $967.66M ▲ | $704.56M ▼ | $263.1M ▲ |
| Q3-2024 | $473.31M | $957.73M | $720.02M | $237.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.16M ▲ | $8.26M ▲ | $20.54M ▼ | $-1.57M ▲ | $27.84M ▲ | $4.17M ▲ |
| Q2-2025 | $-52.4M ▲ | $-9.5M ▲ | $58.13M ▲ | $-39.71M ▼ | $10.54M ▲ | $-15.7M ▲ |
| Q1-2025 | $-130.56M ▼ | $-18.28M ▼ | $9.19M ▲ | $-4.69M ▼ | $-15.66M ▼ | $-21.24M ▼ |
| Q4-2024 | $755K ▲ | $10.72M ▼ | $5.01M ▲ | $2.3M ▲ | $20.2M ▲ | $7.65M ▼ |
| Q3-2024 | $-23.25M | $26.78M | $-19.9M | $-4.52M | $1.34M | $21.54M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Pump | $110.00M ▲ | $100.00M ▼ | $110.00M ▲ | $110.00M ▲ |
 Supplies and Other | $130.00M ▲ | $130.00M ▲ | $130.00M ▲ | $140.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $70.00M ▲ | $70.00M ▲ | $70.00M ▲ | $80.00M ▲ |
 UNITED STATES | $210.00M ▲ | $170.00M ▼ | $180.00M ▲ | $150.00M ▼ |
CEO
John F. Sheridan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-10-10 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 159
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Stifel
Buy
Baird
Outperform
Oppenheimer
Outperform
RBC Capital
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:12.1M
Value:$252.56M
BLACKROCK INC.
Shares:11.12M
Value:$232.13M
VANGUARD GROUP INC
Shares:7.06M
Value:$147.41M
Summary
Showing Top 3 of 319